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Background. In this phase 2 study, we evaluated the efficacy and safety of oral gepotidacin, a novel triazaacenaphthylene bacter-
ial type II topoisomerase inhibitor, for the treatment of uncomplicated urogenital gonorrhea.
Methods. Adult participants with suspected urogenital gonorrhea were enrolled and completed baseline (day 1) and test-of-cure 
(days 4–8) visits. Pretreatment and posttreatment urogenital swabs were collected for Neisseria gonorrhoeae (NG) culture and sus-
ceptibility testing. Pharyngeal and rectal swab specimens were collected if there were known exposures. Participants were stratified 
by gender and randomized 1:1 to receive a 1500-mg or 3000-mg single oral dose of gepotidacin.
Results. The microbiologically evaluable population consisted of 69 participants, with NG isolated from 69 (100%) urogenital, 
2 (3%) pharyngeal, and 3 (4%) rectal specimens. Microbiological eradication of NG was achieved by 97%, 95%, and 96% of partic-
ipants (lower 1-sided exact 95% confidence interval bound, 85.1%, 84.7%, and 89.1%, respectively) for the 1500-mg, 3000-mg, and 
combined dose groups, respectively. Microbiological cure was achieved in 66/69 (96%) urogenital infections. All 3 failures were NG 
isolates that demonstrated the highest observed gepotidacin minimum inhibitory concentration of 1 µg/mL and a common gene 
mutation. At the pharyngeal and rectal sites, 1/2 and 3/3 NG isolates, respectively, demonstrated microbiological cure. There were 
no treatment-limiting adverse events for either dose.
Conclusions. This study demonstrated that single, oral doses of gepotidacin were ≥95% effective for bacterial eradication of NG 
in adult participants with uncomplicated urogenital gonorrhea.
Clinical Trials Registration. NCT02294682.
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Gonorrhea is a sexually transmitted infection caused by Neisseria 
gonorrhoeae (NG), with 78 million infections reported globally in 
2012 [1]. In the United States, approximately 468 500 gonococcal 
infections were reported in 2016, an 18.5% increase from 2015 [2], 
while in Europe, approximately 66 000 gonococcal infections were 
reported in 2014, a 25% increase from 2013 [3]. Consequences of 
untreated gonococcal infections include pelvic inflammatory dis-
ease, infertility in women and men, ectopic pregnancy, tubo-ovarian 
abscess, neonatal conjunctivitis, and disseminated gonorrhea [4].
Over the past few decades, NG has demonstrated the ability 
to develop resistance to most antibiotics recommended or used 
for treatment [5–7], suggesting the possibility of untreatable 
gonorrhea in the future [8–10]. The Centers for Disease Control 
and Prevention and the World Health Organization have labe-
led drug-resistant NG with threat levels of urgent and high, 
respectively, and identified a critical need for new antibiotic 
treatments [11–14]. Current guidelines recommend first-line 
dual antibiotic therapy that consists of intramuscular ceftriax-
one combined with oral azithromycin [1, 15, 16]. Although this 
approach may delay the emergence of cephalosporin-resistant 
NG, the impending threat remains. Surveillance data demon-
strate increasing minimum inhibitory concentrations (MICs) 
for NG to third-generation extended-spectrum cephalosporins 
and azithromycin in the United States, Canada, and Europe [13, 
17–20]. Several therapeutic options are being evaluated for the 
treatment of gonorrhea, including dual combinations of estab-
lished and novel antibiotics [5, 14, 21–23].
Gepotidacin (GSK2140944) is a novel triazaacenaphthylene 
bacterial type II topoisomerase inhibitor that is currently in 
development [24–29]. Gepotidacin selectively inhibits bacterial 
DNA replication by interacting in a unique way on the GyrA 
subunit of bacterial DNA gyrase and the ParC subunit of bac-
terial topoisomerase IV. Gepotidacin has in vitro activity against 
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pathogens resistant to established antibacterials, including cip-
rofloxacin-resistant and -susceptible strains of NG [30, 31]. In 
this study, we evaluated the efficacy of single, oral doses of gepo-
tidacin for treatment of uncomplicated urogenital gonorrhea.
METHODS
Study Design
This phase 2, randomized, multicenter, open-label, dose-rang-
ing study was conducted at 12 sites (11 US sites and 1 UK site) 
from April 2015 to August 2016 to evaluate the efficacy, safety, 
tolerability, and plasma exposures of 2 single oral doses of gepo-
tidacin in uncomplicated urogenital gonorrhea. Throughout the 
study, real-time sponsor-blinded reviews of safety data and NG 
isolate identification and susceptibilities by GlaxoSmithKline 
review teams were conducted. Additionally, an independent 
review team had the authority to recommend discontinuation 
of a dose, continue randomization as planned, or end the trial 
due to success or futility (Figure 1). The study was conducted in 
accordance with the International Council for Harmonisation 
of Technical Requirements for Pharmaceuticals for Human Use, 
Good Clinical Practice, and applicable country-specific require-
ments, including institutional review board and ethics commit-
tee approvals. Participants provided written, informed consent 
before any study procedures were performed.
Participants
Men and nonpregnant, nonlactating women aged ≥18 years who 
had suspected uncomplicated urogenital gonorrhea, defined 
as the presence of purulent urethral or cervical discharge upon 
physical examination and a prior culture or nucleic acid amp-
lification test (NAAT) positive for NG, a Gram stain positive 
for gram-negative diplococci from male urethral specimens, or 
reported sexual contact with a partner diagnosed with gonorrhea 
within the past 14 days were enrolled.
Exclusion criteria included a body mass index ≥40.0  kg/m2; 
hysterectomized women without a cervix; men diagnosed with 
epididymitis or orchitis; a medical condition or required medica-
tion that may have been aggravated by acetylcholinesterase inhibi-
tion; diagnosis of Clostridium difficile (CD) infection; liver disease; 
prespecified baseline electrocardiogram (ECG) abnormalities and 
cardiovascular conditions; disseminated gonococcal infections; 
antibiotic treatment within 14 days; or taking medications with a 
known risk of torsades de pointes. Participants agreed to abstain 
from or to use a male condom for any sexual activity from baseline 
through test-of-cure (TOC) to prevent reinfection.
Participant Evaluation and Therapy
The total study duration was approximately 1 week with 2 study 
visits: baseline (day 1) and TOC (days 4–8). At baseline, a physi-
cal examination, assessment of vital signs, clinical laboratory tests, 
and ECGs were performed. Baseline microbiology procedures 
included collection of pretreatment urogenital swab specimens for 
NG culture from all participants; a Gram stain was performed on 
male urogenital specimens. From areas of known exposure, pre-
treatment pharyngeal and rectal swab specimens for NG culture 
were collected. Pretreatment urogenital swab or urine specimens 
for detection of NG and Chlamydia trachomatis (CT) by NAAT 
assay were obtained at baseline only. Eligible participants were 
stratified by gender and randomized 1:1 to receive a 1500-mg 
(3 × 500-mg capsules) or 3000-mg (6 × 500-mg capsules) single 
oral dose of gepotidacin administered open label with food at the 
clinic (Figure 1). Dose selection was based on in vitro and in vivo 
data and pharmacokinetic modeling, which indicated the low and 
high doses would provide systemic exposures to cover urogenital 
NG isolates with gepotidacin MICs of 0.5  µg/mL and 1  µg/mL, 
respectively. At 2 hours postdose, ECG and blood pharmacokinetic 
sample collection were performed. Based on blinded, real-time 
assessment of systemic exposures and ECG data from the first 37 
participants, the sponsor safety review team determined postdose 
ECG and pharmacokinetic requirements could be safely removed.
Participants returned to the clinic at TOC for safety procedures 
similar to baseline and adverse event (AE) and concomitant med-
ication data collection. At TOC, posttreatment urogenital swab 
specimens were collected for NG culture (and Gram stain for 
male urogenital specimens) from all participants who were posi-
tive for NG at baseline. Posttreatment pharyngeal and rectal swab 
specimens were also collected from anatomical sites that had a 
positive baseline NG culture. Standard-of-care treatment for CT 
was allowed after all TOC procedures were complete.
Microbiological Evaluation
Gram stain, NG culture, and presumptive organism identifica-
tion were performed at local laboratories. Recovered isolates of 
presumptive NG were sent to central laboratories (Q2 Solutions, 
Valencia, California, and University of Alabama, Birmingham) 
for confirmation of identification and susceptibility testing Figure 1. Study design.
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by agar dilution based on Clinical and Laboratory Standards 
Institute guidelines. Microbiological outcome (bacterial eradica-
tion, bacterial persistence, or unable to determine) and response 
(microbiological success or failure) for NG at TOC were deter-
mined based on predefined criteria. NG and CT NAATs were 
performed using the US Food and Drug Administration–cleared 
commercially available methods at local laboratories.
Statistical Analyses
Participants were randomized into the study until approximately 
30 microbiologically evaluable (ME) participants were included 
in each treatment arm (defined as all randomized participants 
who had NG isolated from baseline cultures of urogenital swab 
specimens, received either dose of gepotidacin, and returned for 
TOC). Assuming the true cure rate was 95%, a sample size of 30 
ME participants was expected to provide at least 80% power to 
detect a difference of 15% (ie, cure rate of 95% under the alter-
native hypothesis and ≤80% under the null hypothesis) using a 
1-sided binomial test at the 0.05 significance level.
The primary efficacy endpoint was the culture-confirmed bac-
terial eradication of urogenital NG at TOC (microbiological suc-
cess). The null hypothesis (cure rate ≤80%) was tested using the 
binomial test for each dose level. To control the type I error rate of 
the final analysis at <0.05, a closed-testing procedure was used that 
required establishing significance at the higher dose before assess-
ing the significance at the lower dose. The 2-sided 90% exact con-
fidence interval (CI) was produced to reflect the 1-sided α = 0.05 
[32]. If the 95% 1-sided CI for a dose level included 80%, then 
the null hypothesis was not rejected for that dose level. Subgroup 
analyses for age (18–64, 65–74, and ≥ 65 years) and gender were 
also performed. All analyses were conducted using SAS software, 
version 9.2 (SAS Institute, Inc., Cary, North Carolina).
Safety was assessed in all randomized participants who 
received either dose of gepotidacin. The safety secondary end-
point was evaluated by the analysis of AEs, including predefined 
cardiovascular and gastrointestinal AEs of special interest, vital 
sign assessments, laboratory values, physical examinations, and 
ECG parameters. The exploratory endpoints were bacterial 
eradication of pharyngeal and rectal NG when positive at base-
line, microbiological characteristics of the isolates recovered, 
and a descriptive statistical summary of gepotidacin plasma 
concentrations. Gepotidacin plasma concentrations were also 
compared with phase 1 data from healthy volunteers.
RESULTS
Participant Population
A total of 106 participants were randomly assigned to 1500 mg 
(n = 53) or 3000 mg (n = 53) gepotidacin (Figure 2). One ran-
domized participant (1500 mg) did not receive study treatment 
and 37 participants did not have NG isolated at baseline; thus, 
the ME population consisted of 69 participants (30 participants 
in the 1500-mg group and 39 in the 3000-mg treatment group).
The majority of participants were men (95%) and black (48%) 
with a mean age of 33.3  years; only 5 women were enrolled 
(Table 1). Based on NAAT results, 68 of 106 participants (64%) 
were positive for NG, 9 participants (8%) were positive for CT, 
and 4 (4%) were positive for both. The majority of Gram stain 
results for male urogenital specimens revealed the presence of 
white blood cells with gram-negative diplococci. In the ME 
population, NG isolates were identified in 69/69 (100%) uro-
genital, 2/69 (3%) pharyngeal, and 3/69 (4%) rectal specimens 
(Table 2). Of the urogenital NG isolates, 97% (67/69) were from 
men and 3% (2/69) were from women. Pharyngeal and rectal 
baseline NG isolates were recovered from men only.
Treatment Outcomes
The primary protocol-defined endpoint was met overall and in 
both treatment groups (Table 3).
Microbiological success for urogenital gonorrhea was achieved 
by 97%, 95%, and 96% of participants (lower 1-sided exact 95% 
CI bound, 85.1%, 84.7%, and 89.1%, respectively) for the 1500-
mg, 3000-mg, and combined dose groups, respectively. The ME 
population included 2 women, 1 in each treatment group, both of 
whom were microbiological successes for urogenital NG. Three 
participants (4%; 1 participant who received 1500 mg and 2 par-
ticipants who received 3000 mg) were microbiological failures.
Analysis of subgroups was limited because the majority of 
study participants were in the age group of 18 to 64 years and 
were men. Only 2 participants had pharyngeal NG at base-
line, both in the 3000-mg treatment group; 1 participant was a 
microbiological success and the other participant was a micro-
biological failure (Table 3). All 3 participants with rectal NG at 
baseline were microbiological successes, with 1 participant in 
the 1500-mg treatment group and 2 participants in the 3000-mg 
treatment group (Table 3). All microbiological failures received 
standard-of-care ceftriaxone 250 mg intramuscularly and azith-
romycin 1 g orally per national treatment guidelines.
In Vitro Susceptibility Testing
In the ME population, of the 69 baseline urogenital NG iso-
lates, 23/69 (33%), 19/69 (28%), and 14/69 (20%) were resist-
ant to ciprofloxacin, penicillin, and tetracycline, respectively 
(Table 4). All of the baseline urogenital NG isolates were sus-
ceptible to cefixime, ceftriaxone, and spectinomycin.
In the ME population, gepotidacin was active in vitro against 
the 69 urogenital NG isolates recovered, with overall MIC 
50% and 90% values of 0.12  µg/mL and 0.5  µg/mL, respec-
tively (Table  5), and MICs ranging from ≤0.06 to 1  µg/mL. 
Gepotidacin MICs ranged from ≤0.06 to 0.25  µg/mL against 
the pharyngeal (n = 2) and rectal (n = 3) NG isolates recovered.
All 3 participants who were urogenital microbiological fail-
ures had baseline NG isolates with a gepotidacin MIC of 1 µg/
mL, which was the highest baseline gepotidacin MIC value 
observed in this study. Subsequent sequencing of the quinolone 
resistance-determining region (QRDR) of GyrA and ParC in 
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these isolates revealed that all 3 isolates were quinolone resist-
ant and had a preexisting D86 substitution due to a mutation 
in the parC gene, which is known to affect gepotidacin bind-
ing. Resistance also emerged between baseline and TOC for 2 
of these urogenital microbiological failures, both in the high-
dose 3000-mg treatment group. The gepotidacin MIC for both 
NG isolates from these 2 failures increased from 1  µg/mL to 
≥32 µg/mL between baseline and TOC, and both TOC isolates 
were found to have an additional A92T substitution due to a 
mutation in the gyrA gene. For the 1 pharyngeal microbiologi-
cal failure, the NG isolate had no change in gepotidacin MIC 
from baseline to TOC (0.12 µg/mL at both time points) and no 
mutations were observed in the QRDR of GyrA or ParC.
Safety and Tolerability
There were no treatment-limiting AEs for either gepotidacin 
dose. Adverse events occurred in 27 of 52 (52%) and 34 of 53 
(64%) participants in the 1500-mg and 3000-mg treatment 
groups, respectively (Table 6). No AEs led to study withdrawal 
and no deaths or serious AEs were reported. The most fre-
quently reported AEs (>10% total) were diarrhea (27%), flatu-
lence (23%), abdominal pain (15%), and nausea (13%). For 
nausea and diarrhea, the comparative relative risk 95% CIs were 
>1, suggesting a higher risk in the 3000-mg treatment group 
for these 2 AEs. The majority of AEs were mild to moderate in 
intensity, with 2 severe AEs, 1 each of flatulence (1500 mg) and 
dizziness (3000 mg).
Cardiovascular AEs were reported in 2 participants (ECG ST 
segment elevation and palpitations) in the 1500-mg treatment 
group and 1 participant (tachycardia) in the 3000-mg treatment 
group. Investigators considered only the mild tachycardia as 
treatment related in a participant who had no underlying car-
diovascular history. There were no dose-related trends observed 
for clinical laboratory evaluations, vital signs, or ECGs.
Figure 2. Participant disposition flow diagram. Abbreviations: ME, microbiologically evaluable; NG, Neisseria gonorrhoeae; PK, pharmacokinetic; TOC, test-of-cure.
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Pharmacokinetics
The mean gepotidacin plasma concentrations (coeffi-
cient of variations) for the 2-hour postdose time point 
were 2.89  µg/mL (62.2%) and 6.35  µg/mL (42.9%) for the 
1500-mg (n  =  34) and 3000-mg (n  =  36) single oral doses 
of gepotidacin, respectively, which was a dose proportional 
increase. A  comparison of gepotidacin plasma concentra-
tions between participants in the present study and phase 1 
healthy volunteers showed comparable 2-hour postdose con-
centrations (Figure 3).
DISCUSSION
As resistance to established antibiotics continues to rise for NG, 
new therapeutic options are needed to treat gonococcal infections. 
Gepotidacin is in development for the treatment of uncomplicated 
urogenital gonorrhea and is a first-in-class triazaacenaphthylene 
Table 1. Demographics and Baseline Characteristics in the All Randomized Population
Characteristic Gepotidacin 1500 mg (n = 53) Gepotidacin 3000 mg (n = 53) Total (N = 106)
Age, years
 Mean (range) 34.1 (18–63) 32.4 (18–69) 33.3 (18–69)
 18–64 53 (100) 52 (98) 105 (>99)
 65–74 0 1 (2) 1 (<1)
Sex
 Female 3 (6) 2 (4) 5 (5)
 Male 50 (94) 51 (96) 101 (95)
Race
 Black 22 (46) 25 (50) 47 (48)
 White 24 (50) 21 (42) 45 (46)
 American Indian or Alaska native 1 (2) 1 (2) 2 (2)
 Asian 1 (2) 1 (2) 2 (2)
 Native Hawaiian or other Pacific Islander 0 1 (2) 1 (1)
 White and black heritage 0 1 (2) 1 (1)
Nucleic acid amplification testa
Neisseria gonorrhoeae
 Positive 31 (58) 37 (70) 68 (64)
 Negative 22 (42) 14 (26) 36 (34)
 Presence or absence cannot be determined 0 2 (4) 2 (2)
Chlamydia trachomatis
 Positive 6 (11) 3 (6) 9 (8)
 Negative 47 (89) 48 (91) 95 (90)
 Presence or absence cannot be determined 0 2 (4) 2 (2)
Data are presented as number (%) unless otherwise indicated. For the nucleic acid amplification test (NAAT) summary, the number of randomized participants in each respective treatment 
group or total was used as the denominator for the percentage calculation.
aThe NAAT assay was reported at baseline for urogenital specimens only.
Table 2. Summary of Neisseria gonorrhoeae Recovery Rate at Baseline in the Microbiologically Evaluable Population
Specimen Source
Gepotidacin
1500 mg (n = 30)
Gepotidacin
3000 mg (n = 39) Total (N = 69)
Number Recovery Rate (%) Number Recovery Rate (%) Number Recovery Rate (%)
Urogenital
 Overall 30 100 39 100 69 100
 Male 29 97 38 97 67 97
 Female 1 3 1 3 2 3
Pharyngeal
 Overall 0 ... 2 5 2 3
 Male 0 ... 2 5 2 3
 Female 0 ... 0 ... 0 ...
Rectal
 Overall 1 3 2 5 3 4
 Male 1 3 2 5 3 4
 Female 0 ... 0 ... 0 …
The numbers of participants in the treatment groups and total were used as denominators.
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antibiotic with a novel mechanism of action. Gepotidacin given 
alone as a single oral dose (3 or 6 capsules) was ≥95% effective for 
bacterial eradication of culture-proven uncomplicated urogenital 
gonorrhea in this study. Gepotidacin may prove to be a therapeu-
tic alternative for the treatment of uncomplicated gonorrhea. NG 
can demonstrate various resistance mechanisms [5–7]. To main-
tain the efficacy of gepotidacin and to help preserve the efficacy 
of other antibacterials, different dosing strategies for gepotidacin, 
including dual-agent therapy, may ultimately be needed.
For baseline urogenital NG isolates with gepotidacin MICs 
≤0.5 µg/mL, the microbiological success rate was 100% in both 
treatment groups (n = 28, 1500 mg; n = 36, 3000 mg). Three 
urogenital microbiological failures were observed; all had iso-
lates with the highest observed gepotidacin MIC of 1  µg/mL 
together with a common gene mutation known to affect gepo-
tidacin binding; and all were men who have sex with men. 
Emergence of resistance to gepotidacin was observed for 2 of 
the urogenital microbiological failures. Further clinical devel-
opment of gepotidacin for gonorrhea will need to consider dose 
optimization strategies and options to address NG isolates with 
higher gepotidacin MICs to minimize the potential for emer-
gence of resistance.
With the single gepotidacin doses administered, there were 
no observed dose-limiting AEs. Blinded real-time reviews of 
safety data supported the randomization of participants to 
both the low- and high-dose groups throughout the study. 
The most frequently reported AEs were gastrointestinal in 
nature. Gepotidacin was administered with food in this study 
to minimize these effects. Such AEs have been observed pre-
viously for gepotidacin [26–29, 33] and are well known to be 
associated with some antibacterial therapies. CD infections 
were not reported in this study. Adverse events potentially 
associated with acetylcholinesterase inhibition, a known effect 
of gepotidacin based on in vitro competitive and reversible 
inhibition of the enzyme at clinically relevant concentrations 
[28], include dizziness, hyperhidrosis, and headache and were 
experienced by ≤6 participants in either treatment group. 
Potential dose-related trends were observed for some gastro-
intestinal and acetylcholinesterase inhibition AEs, but statisti-
cal significance could not be declared due to the small number 
of participants.
Table  4. Urogenital Baseline Neisseria gonorrhoeae Antimicrobial 
Resistance for Selected Antimicrobials in the Microbiologically Evaluable 
Population
Antimicrobial Agent
n (%) of Resistant Isolatesa
Gepotidacin
1500 mg
Gepotidacin
3000 mg Total
Number of isolates 30 39 69
Cefixime 0 0 0
Ceftriaxone 0 0 0
Ciprofloxacin 8 (27) 15 (38) 23 (33)
Penicillin 10 (33) 9 (23) 19 (28)
Spectinomycin 0 0 0
Tetracycline 6 (20) 8 (21) 14 (20)
Isolates were defined as resistant based on Clinical and Laboratory Standards Institute 
(CLSI) guidelines. For cefixime and ceftriaxone, a susceptible only breakpoint was applied. 
Only drugs with CLSI breakpoints were included in the summary table. The counts in this 
table indicate the number of isolates, not the number of participants.
aOf the 2 pharyngeal Neisseria gonorrhoeae (NG) baseline isolates, susceptibility results 
were only available for 1 isolate, which was resistant to ciprofloxacin, penicillin, and tetracy-
cline. Of the 3 rectal NG baseline isolates, 2 were resistant to tetracycline.
Table 3. Summary of Bacterial Eradication by Culture for Urogenital, Pharyngeal, and Rectal Neisseria gonorrhoeae in the Microbiologically Evaluable 
Population
Microbiological Response–Microbiological Outcome
Gepotidacin
1500 mg
Gepotidacin
3000 mg Total
Participants with urogenital NG at baseline 30 39 69
 Microbiological success 29 (97) 37 (95) 66 (96)
  1-sided 95% confidence interval (85.1, 100) (84.7, 100) (89.1, 100)
  1-sided P value 0.011 0.009 <0.001
  Bacterial eradication 29 (97) 37 (95) 66 (96)
 Microbiological failure 1 (3) 2 (5) 3 (4)
  Bacterial persistence 1 (3) 2 (5) 3 (4)
  Unable to determine 0 0 0
Participants with pharyngeal NG at baseline 0 2 2
 Microbiological success 0 1 (50) 1 (50)
  Bacterial eradication 0 1 (50) 1 (50)
 Microbiological failure 0 1 (50) 1 (50)
  Bacterial persistence 0 1 (50) 1 (50)
Participants with rectal NG at baseline 1 2 3
 Microbiological success 1 (100) 2 (100) 3 (100)
  Bacterial eradication 1 (100) 2 (100) 3 (100)
Data are presented as number (%) unless otherwise indicated. If either the count of successes or the count of failures was ≤5, then exact tests were conducted to compute P values.
Abbreviation: NG, Neisseria gonorrhoeae.
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The effect of gepotidacin on cardiac conduction has been 
thoroughly evaluated [33], with results demonstrating a mild 
increased heart rate effect and a predicted mean QT prolonga-
tion of <15 milliseconds at plasma concentrations of 9 µg/mL, 
which is the highest plasma exposure expected clinically. With 
the high dose of 3000 mg in this study, mean 2-hour postdose 
plasma concentrations were approximately 6 µg/mL and were 
below the predicted QT threshold (<10 milliseconds), with no 
significant cardiac safety observations.
A comparison of gepotidacin plasma concentrations between 
participants in the present study and phase 1 healthy volunteers 
showed comparable 2-hour postdose concentrations (Figure 3). 
This phase 2 population consisted primarily of otherwise 
healthy participants; therefore, systemic exposures similar to 
those observed in phase 1 populations were expected.
One limitation of this study was the sample size, and a larger 
trial will be needed to confirm these results. Additionally, enroll-
ment focused on participants with uncomplicated urogenital 
gonorrhea and few participants with pharyngeal or rectal gon-
orrhea were enrolled. Of these, 1 of 2 pharyngeal and all 3 rectal 
Table  5. Summary of Baseline Minimum Inhibitory Concentration Results for Gepotidacin Against Neisseria gonorrhoeae in the Microbiologically 
Evaluable Population
Specimen Source
 Treatment n
MIC Range
MIC50 (μg/mL) MIC90 (μg/mL)Minimum (μg/mL) Maximum (μg/mL)
Urogenital
 Gepotidacin 1500 mg 30 ≤0.06 1 0.12 0.5
 Gepotidacin 3000 mg 39 ≤0.06 1 0.25 0.5
 Gepotidacin total 69 ≤0.06 1 0.12 0.5
Pharyngeal
 Gepotidacin 1500 mg ... ... ... ... ...
 Gepotidacin 3000 mg 2a ≤0.06 0.12 ... ...
 Gepotidacin total 2a ≤0.06 0.12 ... ...
Rectal
 Gepotidacin 1500 mg 1 0.12 0.12 ... ...
 Gepotidacin 3000 mg 2 0.12 0.25 ... ...
 Gepotidacin total 3 0.12 0.25 ... …
The MIC50 and MIC90 values were not reported if n <10.
Abbreviations: MIC, minimum inhibitory concentration; MIC50, minimum inhibitory concentration required to inhibit the growth of 50% of organisms; MIC90, minimum inhibitory concentra-
tion required to inhibit the growth of 90% of organisms.
aDue to specimen contamination, susceptibility testing could not be reliably performed on the pharyngeal isolate from 1 participant in the 3000-mg treatment group at baseline.
Table  6. Adverse Event Overview and Summary of Common Adverse 
Events by Preferred Term in the Safety Population
AE Category
Gepotidacin 
1500 mg 
(n = 52)
Gepotidacin 
3000 mg 
(n = 53) Total (N = 105)
Any AE 27 (52) 34 (64) 61 (58)
 Related to study treatment 24 (46) 33 (62) 57 (54)
 Leading to study withdrawal 0 0 0
Any serious AE 0 0 0
Common AEs by preferred term
 Diarrhea 9 (17) 19 (36) 28 (27)
 Flatulence 14 (27) 10 (19) 24 (23)
 Abdominal pain 6 (12) 10 (19) 16 (15)
 Nausea 3 (6) 11 (21) 14 (13)
 Fatigue 3 (6) 5 (9) 8 (8)
 Dizziness 1 (2) 6 (11) 7 (7)
 Hyperhidrosis 1 (2) 6 (11) 7 (7)
 Abdominal discomfort 4 (8) 2 (4) 6 (6)
 Feeling hot 1 (2) 4 (8) 5 (5)
 Eructation 1 (2) 3 (6) 4 (4)
 Feces soft 1 (2) 3 (6) 4 (4)
 Somnolence 0 3 (6) 3 (3)
Data are presented as number (%). Common adverse events were defined as an AE with 
≥5% incidence in any treatment group.
Abbreviations: AE, adverse event.
Figure  3. Comparison of gepotidacin single-dose plasma concentrations at 2 
hours postdose between phase 2 participants with gonorrhea and phase 1 healthy 
volunteers. The solid midline is the mean and the broken midline is the median. The 
phase 1 data are from a single oral dose under fed conditions for 1500 mg and a 
single oral dose under fasted conditions for 3000 mg. The 1500-mg and 3000-mg 
phase 2 data are from the present study, which was a single oral dose administered 
with food.
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gonococcal infections were eradicated, indicating potential effi-
cacy. Both men and women were enrolled; however, only 3% 
of the ME population were women. Future investigations will 
aim for a higher enrollment of women, but there will be limi-
tations due to required reproductive health exclusions. Future 
studies will also collect sexual orientation for all participants 
to allow further assessment of resistance patterns. The ME 
population consisted of only US participants; thus, these study 
results may not reflect global NG epidemiology and resistance 
patterns. Last, coinfection with CT is common in individuals 
with gonorrhea [34]. Gepotidacin has not been shown to have 
activity against CT; thus, standard-of-care therapy was allowed 
after completing TOC assessments for participants who tested 
positive at baseline.
In conclusion, these results demonstrated that 1500-mg and 
3000-mg single oral doses of gepotidacin were ≥95% effect-
ive for bacterial eradication of NG in adult participants with 
uncomplicated urogenital gonorrhea. Emergence of high-level 
resistance in 2 of 3 treatment failures is a concern. However, 
new therapies for drug-resistant NG are urgently needed. With 
additional clinical evaluation, gepotidacin may provide a much 
needed oral therapeutic option for uncomplicated urogenital 
gonorrhea as part of a new combination regimen.
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